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Abstract
Lipoproteins can bind lipopolysaccharide (LPS) and de­
crease the LPS-stimuIated production of pro-inflammatory 
cytokines. We investigated the effect of increased plasma 
concentrations of low-density-Iipoproteins (LDL) on sur­
vival and cytokine production after a lethal challenge with 
either LPS or live Gram-negative bacteria in LDL receptor 
deficient mice (LDLR—/ —). The LDLR—/— mice chal­
lenged with LPS had an eightfold increased LD50 when 
compared with the wild type controls (C57B1/6J), while tu­
mor necrosis factor a  (TNFa) and interleukin-1 a (IL-la) 
plasma concentrations were decreased twofold. LDLR-7 — 
mice had significantly lower and delayed mortality than 
control mice after infection with Klebsiella pneumoniae. No 
differences in the outgrowth of bacteria in the organs were 
present between the two groups, while circulating cytokine 
concentrations were decreased twofold in LDLR—/™ mice* 
In contrast, the LPS-stimulated in vitro production of cyto­
kines by peritoneal macrophages of LDLR—/— mice was 
significantly increased compared with controls. This in­
crease was associated with enhanced specific binding of 
LPS to the macrophages of L D L R -/- mice. In conclusion, 
endogenous LDL can protect against the lethal effects of en­
dotoxin and Gram-negative infection. At least part of this 
protection is achieved through decreased in vivo production 
of pro-inflammatory cytokines, in spite of increased cyto­
kine production capacity. (J. Clin. Invest 1996. 97:1366- 
1372). Key words: lipopolysaccharide« gram-negative infec­
tion • tumor necrosis factor • interleukin-1 • low-density li­
poproteins.
Introduction
Mammals infected with Gram-negative bacteria may develop 
a severe syndrome characterized by hypotension, disseminated 
intravascular coagulation, and renal, hepatic and cerebral
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damage. Most of these deleterious effects can be mimicked by 
infusion of endotoxin, a lipopolysaccharide (LPS) component 
of the cell wall of Gram-negative bacteria (1). Binding of LPS 
to various receptors on leukocytes triggers the production and 
release of proinflammatory cytokines as tumor necrosis factor 
a  (TNFa), interleukin-la (IL-la) and IL-ip. In experimental 
models, treatment of animals with anti-TNF antibodies attenu­
ates the lethal effects of endotoxin or Gram-negative bacteria 
(2, 3). A  protective effect can also be obtained by treatment 
with either of the natural antagonists of TNF or IL-1, soluble 
TNF receptors or IL-1. receptor antagonist (4, 5). Thus, these 
cytokines are thought to play a central role in the pathophysi­
ology of sepsis.
Once LPS enters the circulation, initial interactions with 
LPS-binding protein (LBP) and lipoproteins play a critical role 
in subsequent stimulation of pro-inflammatory cytokine syn­
thesis. The LPS-LBP complex is bound by CD 14, the cellular 
receptor for LBP, and this binding stimulates macrophages to 
release pro-inflammatory cytokines (6, 7). Recent studies also 
suggest that LBP may facilitate the binding of LPS not only to 
CD 14, but also to lipoproteins (8), either by direct action of 
LBP or by a two-step reaction in which LPS is first transferred 
to sCD14 and subsequently to H D L  (9). In plasma, LPS bind 
to the various types of lipoproteins: high-density lipoproteins 
(HDL) (10), low-density lipoproteins (LDL) (11), very-low- 
density lipoproteins (VLDL) (12) and chylomicrons (13). For­
mation of LPS-lipoproteins complexes greatly reduces the 
binding of LPS to macrophages (14,15). In vitro, this results in 
decreased production and release of the pro-inflammatory cy­
tokines TNF, IL-1 and IL-6 (16,17), and a subsequent loss of 
LPS toxicity.
The potential protective effect of lipoproteins against LPS- 
toxicity in vivo has been investigated in recent studies. Preiiv- 
cubation of LPS with lipoproteins prior to injection into ani­
mals decreased the mortality (10), while the in vivo infusion of 
lipoproteins markedly reduced the cytokinemia and mortality 
after LPS administration (18). Transgenic mice that express 
human apolipoprotein A -l at high levels and thus have ele­
vated plasma H DL concentrations are protected against LPS 
challenge (19). In contrast, hypolipidemic mice are more sensi­
tive to the toxic effects of endotoxin (20).
All these studies have shown a protection by lipoproteins 
against LPS effects, while only one recent study has reported 
that hyperlipoproteinemia may beneficially influence severe 
infections with live microorganisms (21). In a rat model of ce­
cal ligation and puncture, infusion of exogenous chylomicrons 
reduced both circulating LPS and TNF concentrations and 
mortality. However, no data regarding the effect of endoge­
nously elevated lipoprotein concentrations on severe infec­
tions have been reported. In the present study, we assessed the 
effects of a lethal LPS challenge and a lethal Gram-negative 
infection with Klebsiella pneum oniae  in the recently developed
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low density lipoprotein receptor knockout mice (L D L R -/—). 
These LDLR—/ — mice have a markedly increased plasma 
cholesterol concentration compared with the wild-type con­
trols, due to a 7-9-fold increase in intermediate density lipo­
proteins (IDL) and LDL (22). To study the mechanisms in­
volved in the lipoprotein-induced protection we assessed the 
bacterial outgrowth in the organs and the cytokine response 
during infection. In addition, we studied the cytokine produc­
tion capacity by the peritoneal macrophages of the LDLR —/ -  
and control mice.
Methods
Animals. Homozygous C57B1/6J mice lacking low density lipopro­
tein receptors (L D L R - /—) and wild-type littermates were obtained 
from the Jackson Laboratory (Bar Harbor, ME) as mating pairs, and 
bred in our local facility. For the experiments, 6 -8  weeks old mice, 
weighing 20-25 grams, were used. The animals were fed standard lab­
oratory chow (Hope Farms, Woerden, the Netherlands) and housed 
under specific pathogen-free conditions. The experiments were ap­
proved by the ethical committee on animal experiments of the Catho­
lic University Nijmegen.
Lethal endotoxemia model, Lipopolysaccharide (LPS; Escheri­
chia coli serotype 055:B5) was obtained from Sigma Chemical Co. 
(St. Louis, MO). Groups of LDLR—/— and C57B1/6J mice were in­
jected i.v. in the retroorbital plexus (after anesthetizing with ether) 
with various amounts of LPS (0.25-2.5 mg/mouse). 90 min after chal­
lenge with LPS, five animals from each group were anesthetized with 
ether and bled from the retroorbital plexus for measurement of  
TNFa circulating concentrations. Another five animals per group 
were bled 4 h after LPS for measurement of IL-la and IL-1 p circulat­
ing concentrations. In the remaining mice (at least 5 animals/group), 
survival was assessed daily for 7 d.
Lethal cytokinemia model To investigate the role o f TNF and 
IL-I in the LPS-induced mortality, L D L R —/ -  and control mice re­
ceived a single i.v. injection of recombinant human TNFa (50 |xg/ 
mouse) (kindly provided by Dr. G. Adolf, Ernst-Boehringer Instilut, 
Vienna, Austria), recombinant human IL -la  (10 |i,g/mouse) (kindly 
provided by Dr. P. Lomedico, Hoffmann-LaRoche, Nutley, NJ), or a 
combination of both. Several combinations of recombinant cytokines 
were used in different experiments: 10 fxg TNFa with 1 fig IL -la , 20 
jig TNFa with 5 |xg IL-la, and 50 jxg T N Fa with 20 jjig of IL-la. Sur­
vival was assessed every 12 h for 2 d.
Klebsiella pneumoniae infection. Klebsiella pneumoniae (ATCC  
43816), a strain that produces a lethal infection in normal mice, was 
injected i.v. in the retroorbital plexus (106-107 CFU/mause) into 
L D L R - / -  and control mice (LD50 8 X 105 CFU/C57B1/6J mouse). 
To assess whether the same protection is obtained in a more sus­
tained model of infection, K . pneumoniae  106 CFU/mouse was in­
jected intramuscularly (i.m.) (LD50 5 X i 05 CFU/C57B1/6J mouse) 
into the left thigh muscle of the animals as described (23). Survival 
was assessed daily for 14 d, in groups of at least 18 (i.v. infection) or 9 
animals (i.m. infection). The surviving animals were sacrificed on day 
28 of infection. After 90 min and 4 h, subgroups of five mice were 
killed and blood was collected from retroorbital plexus for the mea­
surement of cytokine concentrations. The outgrowth of the microor­
ganisms from the blood, liver, spleen and kidneys of the animals was 
quantified 24 h after the injection o f  K. pneumoniae. The organs were 
removed aseptically, weighed, and homogenized in sterile saline in a 
tissue grinder. Serial dilutions of the homogenized tissues or blood 
(0.1 ml) were plated on sheep blood agar, and CFU were counted af­
ter overnight incubation at 37°C.
To determine the circulating LPS concentrations, in a separate set 
of experiments groups of 10 L D L R —/ — and control mice were in­
fected i.v. or i.m. with 10fi CFU K. pneumoniae  as described above. 90 
min and 4 h after infection, groups of five animals were anesthetized
and blood collected by intracardiac puncture into 5-ml pyrogen-free 
plastic vials (Falcon; Becton-Dickinson Labware, Lincoln Park, NJ) 
containing 25 IU of pyrogen-free heparin. The tubes were centrifuged 
at 200 g  for 10 min and plasma was collected and stored at -7 0 °C  un­
til assay.
Ex vivo cytokine production. Resident peritoneal macrophages 
were harvested by rinsing the peritoneal cavity aseptically with cold 
PBS containing 0.38% (wt/vol) sodium citrate. After centrifugation 
for 10 min, 1800 cpm, at 4°C, cells were resuspended in RPM1 1640 
(Dutch modification; Flow Laboratories, Irvine, UK), containing 1 mM  
pyruvate, 2 mM L-glutamine and 100 jig/ml gentamicin. 105 cells/well 
were cultured in 96-well microtiter plates (Costar Corporation, Cam­
bridge, M A) in RPMI medium (final volume 200 fxl), with or without 
LPS at a final concentration of 1 jmg/ml. N o  plasma or serum was 
added to the culture medium. The supernatants were collected after 
24 h of incubation at 37°C, and stored at —70°C until assay. To the re­
maining macrophages, 200 pul RPMI 1640 was added, and the cells 
were disrupted by three freeze-thaw cycles to determine the cell-asso­
ciated cytokine contents. The samples were stored at —70°C until 
cytokine measurements.
The cytokine production capacity o f peritoneal macrophages was 
also measured after stimulation by heat-killed (100°C, 30 min) Staph­
ylococcus aureus (ATCC 25923). The suspension was washed three 
times in RPMI (final concentration 2 X 107 CFU/ml). 100 |xl suspen­
sion containing 106 microorganisms in RPMI were added to 105 peri­
toneal macrophages in 96-well microtiter plates and Lhe cells were in­
cubated 24 h at 37°C. The samples were obtained and stored at —70°C 
until cytokine measurements, as described above.
Cytokine measurements. TNFa, IL -la  and IL-1 [3 concentrations 
were determined using specific radioimmunoassays (RIAs) devel­
oped in our laboratory (24). Briefly, standards and samples were di­
luted in RIA-buffer (per liter: 10 mM Na2HP0 4 .2 H 20 ; 12 mM  
EDTA; 1 ml sodium-azide (20% wl/vol); 2.5-gram bovine serum al­
bumin fraction IV (Sigma Chemical Co., St. Louis, MO); 1 ml Triton 
X-1G0; 25 ml aprotinin solution (Trasylol, containing 10,000 inhibitor 
units per milliliter, Bayer BV, Mydrecht, The Netherlands) diluted 
with deionized water milli-Q, pH 7 .4 .100 j j iI of an appropriate mono- 
specific rabbit anti serum against the respective mouse cytokine was 
added to 100 /xl of samples and standards. After vortexing, the tubes 
were incubated for 24 h at 4°C, followed by addition of 100 ¡¿1 of the 
respective 125I-labeled tracers. After 20 h, 750 pd R IA  buffer contain­
ing 9% (wt/vol) polyethylene-glycol 6000, and 3% (vol/vol) goat anti­
rabbit IgG was added. The tubes were incubated for 20 min at room  
temperature and then centrifuged at 1,500 g for 15 min. Supernatants 
were discarded carefully and quickly drained on absorbent paper. R e­
maining radioactivity was counted in a gamma-counter. The radioac­
tivity in control tubes (the non-specific binding activity) was sub- 
stracted from samples and standards. Detection limits were between  
0.02 and 0.04 ng/ml. The mean o f  duplicate determinations was calcu­
lated for each sample. The accuracy of the cytokine assays was deter­
mined using reference preparations: murine recombinant TN Fa, IL- 
la ,  and IL-lp obtained from the National Institute o f Biological 
Standards and Control (NIBSC, Hertfordshire, UK). Using various 
batches of tracers the bias of all cytokine-assays was <  2 0 %; interas­
say precision ranged between 10 and 13% depending on the concen­
tration (n =  22 ).
L P S  measurements. Plasma samples were diluted 1/100 and 1/600 
with apyrogenic saline and heated at 75°C for 5 min before the timu- 
lus assay to remove the effect of serum inhibitors. LPS was deter­
mined in platelet-rich plasma by a chromogenic limulus amoebocyte 
lysate assay (Endosafe Inc., Charleston, SC).
Radioactive labeling o f  LPS. E. coli 055:B 5 LPS was labeled 
with tritium as described previously (25) with minor modifications. 
Briefly, LPS (5 mg/ml) was oxidized with sodium periodate (1.5 mg/ 
ml) in 50 mM acetate buffer, pH 4.0, during 24 h. The remaining peri­
odate was destroyed with ethylene glycol and the LPS was buffer- 
changed and concentrated in an Am icon concentrator (molecular 
cut-off 10,000 D a). 10 mCi [3H] sodium borohydride (specific activity
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21 Ci/mmol) was added to the oxidized LPS (5 mg/ml) in 1 mM Tris- 
HC1, pH 8.0. After a 2 h incubation at room temperature, the reaction 
was terminated by the addition of 25 mg nonradioactive sodium boro- 
hydride. The tritiated LPS was purified on a PD-10 column (Pharma­
cia, Woerden, The Netherlands). Subsequently, the unincorporated 
3H was removed by repeated concentration in an Amicon concentra­
tor. Elution of the 3H-labeled LPS preparation on a PD-10 column in­
dicated that more than 95% of the 3H-label was associated with LPS 
both in the fresh preparation, as well as in the preparation incubated 
overnight at room temperature (the temperature of the incubation in 
the binding studies). The specific activity of this 3H-LPS was 16,000 
cpm/|uLg.
Bindii ig o f  radiolab eled LPS to peritoneal macropi iages. Peri toneal 
macrophages from L D L R —/— and C57B1/6J mice were collected as 
described above, and 106 peritoneal macrophages were incubated in 
100 julI RPMI 1640 in 0.5 ml Eppendorf plastic cups. N o plasma or se­
rum was present in the system. Increasing amounts of [3H-LPS] 
(10 ,000- 100 ,01)0 cpm) were added and the cells were incubated at 
room temperature for 45 min (26). Cells were spun down (2,000 g , 5 
min), washed twice in 100 jxl RPMI, solubilized in scintillation fluid 
and counted in a fj-counter. Nonspecific binding was determined in 
the presence of a large excess of nonradioactive LPS. Specific binding 
of LPS was defined as the difference between total and nonspecific 
binding.
Determination o f  plasma lipids. Cholesterol and triglycerides were 
determined by enzymatic methods on a Hitachi 747 analyzer.
Statistical analysis. Survival data were analyzed using the Kaplan- 
Meyer log rank test (27). Differences in concentrations of cytokines 
and in organ counts of the microorganisms were analyzed using the 
Kruskall-Wallis test (28). Differences were considered significant at 
P <  0.05. All experiments were performed at least twice,
Results
Lethal endotoxemia m o d e l  Plasma cholesterol concentra­
tions are presented in Table I. The total cholesterol concentra­
tions were fourfold higher in L D L R -/— mice at all the time 
points tested. The plasma triglyceride concentrations differed 
only marginally in the two mouse strains both 90 min 
(O.67±0.13 vs. 0.62±0.09 mmol/liter, P  >  0.05) and 4 h 
(0.50±0.07 vs. 0.42±0.06 mmol/liter, P  >  0.05) after LPS. The 
survival of the L D L R -/— mice was significantly increased 
when compared with C57B1/6J mice, the estimated endotoxin 
LD5[) dose being 8-times higher (P  <  0.001) (Fig. 1). Mortality 
occurred in the first 48 h after endotoxin administration, with­
out further mortality during the next days of the follow-up. 
Plasma concentrations of TNFa were significantly lower in 
LDLR—/— mice 90 min after LPS administration, than in con­
trol animals (1.5±0.5 vs. 3.7±0.9 ng/ml, P  <  0.02) (Fig. 2). 
Four hours after the endotoxin challenge, IL-la concentra­
tions were also lower in LDLR—/ — mice (60±21 vs. 106±26 
pg/ml, P  <  0.05), while no differences in IL-1(3 concentrations 
were detected (36±9 vs. 37±9 pg/ml, P >  0.05) (Fig. 2).
Lethal cytokinemia model. To investigate whether the pro­
tection to a lethal injection of endotoxin is due to decreased 
susceptibility to proinflammatory cytokines, mice were in­
jected i.v. with pro-inflammatory cytokines. The administra­
tion of either 50 |xg recombinant human TNFa or 10 \xg IL-la  
did not induce any mortality. After the administration of a 
combination of these cytokines, no protection by the high lipo­
protein concentrations of L D L R - / -  mice was observed. The 
mortality was 0% in both mouse strains when a combination of 
10 |xg of TNFa and 1 |jug IL -la  was injected. When a combina­
tion of 20 ixgTNFa with 5 jjLg IL -la  was injected the mortality
&
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Figure 1. Survival o f L D L R - / -  (A) and C57B1/6J mice ( • )  after 
LPS challenge. Groups of at least five animals received an intrave­
nous LPS challenge with the dosages shown on the x-axis and the out 
come was recorded as percentage mortality after 48 h. LDLR—/ — 
mice bad a significantly improved survival when compared with the 
control animals.
was 20% in LDLR—/— mice and 33% in the C57B1/6J mice 
(P  >  0.05), and when a combination of 50 p,g TNFa with 10 |xg 
IL -la  was injected the mortality was 80% in L D L R - /-  mice, 
and 91% in controls (P >  0.05). The mortality occurred exclu­
sively during the first 48 h.
Klebsiella pneumoniae infection. Cholesterol concentrations 
during K  pneumoniae  infection decreased in both strains of 
mice. However, they remained significantly higher in LDLR—/ -  
mice than in control mice (Table I). No significant differences 
in triglyceride levels 90 min after infection were found be­
tween the LDLR—/ — and C57B1/6J mice (0.79±0.11 vs.
E
O)c
5 r
LL ,z  4 
l -
3 -
2 -
1 -
0
T N F IL-1 a IL-113
Figure 2. Plasma cytokine concentrations in L D L R - / -  (shaded col­
umns) and control mice (black columns) after an intravenous injec­
tion with 1 mg LPS. The plasma concentrations of both TNF (90 min 
after the LPS challenge) and IL -la  (4 h after LPS challenge) were 
significantly decreased in L D L R —/ — mice when compared with con­
trol mice. No differences in IL-lp plasma concentrations were de­
tected 4 h after LPS was injected. *P <  0.05; **P <  0.02.
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0.75±0.06 mmol/liter, P  >  0.05). However, 4 h after infection 
the triglycerides concentrations were slightly higher in 
LDLR—/— mice than controls (0.79±0.21 vs. 0.51 ±0,07 mmol/ 
liter, P  <  0.05). After i.v. injection of 107 CFU of K . pneumo­
niae, LDLR—/ — mice showed a delayed and decreased mor­
tality (70%) compared with control animals (100%, jP <  0.01) 
(Fig. 3). After an i.v. infection with 1CP CFU, only 42% of 
L D L R - / -  mice died, in comparison with 67% of the C57B1/ 
6J mice (P  <  0.05) (Fig. 3). In the K, pneumoniae infection 
models studied, no deaths occurred after 14 d of infection. No 
differences in K. pneumoniae outgrowth in the organs of the 
two groups 24 h after infection was observed (Table II). Also, 
quantitative blood cultures revealed no differences between 
the two mouse strains (Table II). However, the LPS concen­
trations in LDLR—/— mice tended to be lower when com­
pared with C57B1/6J mice, in both strains reaching high values 
90 min after i.v. injection of Klebsiella, and decreasing at 4 h 
(Table III). TNFa concentrations in the plasma of L D L R -/-  
mice measured 90 min after infection were lower compared 
with control mice, although statistical significance was not 
reached (0.45±0.46 vs. 0.81 ±0.61 ng/ml, P >  0.05). Concentra­
tions of IL-la in the plasma of L D L R -/-  mice were lower as 
compared with control mice at 4 h after infection (56±40 vs. 
114±9 pg/ml, P  <  0.04); only marginally lower IL-lp was de­
tected in LDLR—/ -  mice (55±21 vs. 78±13 pg/ml, P >  0.05).
When the more sustained K, pneumoniae infection was in­
duced by intramuscular injection of ICF1 CFU, the survival in 
the L D L R -/— group was 56%, while only 11% of the control 
animals survived (P <  0.05). Most of the animals died between 
days 5 and 12 of the follow-up. No differences in the outgrowth 
of K. pneumoniae  in the organs and blood of the two mouse 
strains were found (Table II). LPS plasma concentrations were 
similar in both mouse strains (Table III). The LPS determina­
tions were performed after heating the plasma, a process 
which liberates lipoprotein-bound LPS, and thus the total 
plasma LPS rather than the free LPS concentrations were as­
sessed. Compared with i.v. infection, the LPS concentrations 
during the i.m. infection were lower 90 min after infection, but 
higher at 4 h. This was also accompanied by later increases in 
cytokines: TNFa and IL-la plasma concentrations in most of 
the samples after 90 min were below the detection limit, to be­
come detectable at 4 h. At the latter time point, a tendency to­
wards decreased circulating concentrations of TNFa (101 ±89
Table I. Plasma Cholesterol Concentrations (mmol/liter) 
before and after L P S  Challenge and K, pneumoniae Infection 
in L D L R - / — and C57B1/6J Mice
L D L R -/- C57B1/6J
Before infection 9.55±1.11 2.25+0.45*
After LPS 90 min 
4 h
5.16±1.53
4.10±0.69
1.42+0.27* 
1,42+0.18s
After K . pneumoniae 90 min 
4 h 
24 h
5,72 ±1.05 
6.27±1.16 
7.42±0.63
1.78±0.08*
1.96±0.175
2.54+0.71*
▼
Table II. Bacterial Outgrowth in the Organs o f  L D L R —/ — and  
C57B1/6J Mice 2 4  h after i.v. and i.m . Infection with 106 CFU  
K. pneum oniae*
L D L R -/- C57B1/6J
K. pneumoniae i.v. Liver 5.78 ±1.09 5.32 ±1.30
Spleen 5.72 ±1.04 6.40 ± 1.02
Kidneys 4.83±1.53 5.32±1.55
Blood 4.63±1.19 5,04 ±1.00
K. pneumoniae i.m. Liver 5.50±1.08 5.25 ±0.71
Spleen 5.52 ±1.57 5.47±0.86
Kidneys 5.42 ±1.46 5.10±0.49
Blood 4.97 ±0.93 5,'12±1.15
*The data represent mean±SD of log CFU/gram of tissue for five ani­
mals. The results do not differ significantly for the three organs and the 
blood tested.
vs. 235 ±228 pg/mL, P >  0.05) and IL-la (35 ±12 vs. 85±52 pg/ 
ml, P >  0.05) was observed in the L D L R - / -  mice when com­
pared with controls, although statistical significance was not 
reached. IL-ip concentrations were below detection limit both 
90 min and 4 h after infection.
Ex vivo cytokine production capacity. To investigate whether 
the decreased in vivo cytokine production by the L D L R -/— 
mice was due to reduced cellular production capacity, rather 
than to LPS binding and neutralization by the high lipoprotein 
concentrations, resident peritoneal macrophages were stimu­
lated in vitro by LPS in the absence of plasma or serum. Some­
what surprisingly, cytokine concentrations in supernatants of 
macrophages from L D L R —/ — mice were 2 -3 -fold higher af­
ter LPS stimulation when compared with C57BI/6J mice (Fig. 
4 a). The cell-associated TNFa did not differ between the two 
mouse strains, while both cell-associated IL-la and IL~1(3 were 
increased in L D L R - / -  mice (Fig. 4 b). This increased cyto­
kine production capacity was observed only after LPS stimula­
tion, and was not detected after stimulation with heat-killed 
Staphylococcus aureus (Fig. 4, a and b),
Binding o f  tritiated L P S  to peritoneal macrophages. To test 
whether the increased cytokine production capacity was due to 
increased LPS binding to macrophages, we assessed the spe­
cific binding of [3H-LPS] to the peritoneal macrophages of the 
two mouse strains. The specific binding of radiolabeled LPS to 
the peritoneal macrophages of L D L R -/— mice was signifi-
Table III  LPS Circulating Concentrations (ng/niL) in 
L D L R —/ — and C57BJ/6J Mice after i.v, and Lm. Infection  
with 106 CFU K. pneum oniae*
L D L R -/ C57D1/6J
IC pneumoniae i.v. 90 min 
4 h
K. pneumoniae i.m. 90 min
4 h
6.7 (3.9-30.5) 
2.9 (1.5-4,2)
2.3 (0.1-49.2) 
13.4 (1.6-26.0)
25.7 (3.5-39.9) 
7.2 (3.8-28.7)s
3.9 (1;7-9,0) 
15.6 (1.9-81.5)
L D L R - /-  and control mice were challenged with LPS (1 mg/mouse) or 
infected i.v. with 106 cfu of K. pneumoniae. Each figure represents 
mean±SD of five mice. *P <  0.01. <  0.05 (for comparison between 
C57B1/6J and L D L R - /- ) .
:i!Thc results represent median (interval) of groups of five mice. §P <  
0.05 (for comparison between LDLR—/ -  and C57B1/6J mice). Total 
LPS plasma concentrations were detected after heating the samples, a 
process which liberates lipoprotein-bound LPS.
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Figure 3. Survival of L D L R —/ — and C57B1/6J mice after i.v. infec­
tion with Klebsiella pneumoniae. A n  i.v. injection of 107 CFU K . 
pneumoniae was given to L D L R - / -  (closed triangles) and C57B1/6J 
mice (closed circles). Other groups of L D L R —/ — (open triangles) 
and C57B1/6J mice (open circles) received 106 CFU K. pneumoniae. 
Survival was significantly improved in L D L R —/ — mice. The figure 
gives pooled data of three experiments with at least 18 mice per 
group each.
cantly higher than to macrophages of C57B1/6J mice, after var­
ious amounts of 3H-LPS added: 2001 ±318 vs. 1132±222 cpm 
bound when 10,000 cpm 3H-LPS were added (P  <  0.05); 
5806±442 vs. 2421 ±476 cpm bound (30,000 cpm added) (P <  
0.05); and 15,840±3,305 vs. 5,901 ±368 cpm bound (100,000 
cpm added) (P <  0.05). The non-specific binding of tritiated 
LPS did not differ between the two mouse strains.
Discussion
In this study we showed that LDL receptor deficient mice 
were protected against lethal endotoxemia as well as against 
severe infections with Gram-negative microorganisms, not 
only after ¿cute i.v. infection, but also in a more subacute 
model of intramuscular infection with Klebsiella pneumoniae. 
Lipoprotein concentrations in the LDLR—/— mice are geneti­
cally elevated, due to increased IDL and LDL (22). Our ap­
proach thus differs from other models in which exogenous li­
poproteins were administered to obtain hyperlipoproteinemia 
(10, 11, 18). This intervention was associated with decreased 
cytokinemia and improved survival during lethal endotoxemia. 
The same protection was reported in mice in which endoge­
nously elevated H DL were responsible for the increased lipo­
proteins (19). The importance of endogenous lipoproteins in 
the protection against lethal endotoxemia was also observed 
by Feingold and colleagues (20), who reported increased LPS- 
induced mortality when serum lipids were decreased by phar­
macological agents. However, our study shows that the pro­
tection due to increased endogenous LDL can be extended to 
severe Gram-negative infections with live microorganisms.
In general, mortality to infection is considered to be due to 
lethal cytokinemia or to functional impairment by excessive 
growth of microorganisms in the organs of the host. In the model 
of infection we studied, showing no difference in the number 
of circulating bacteria or the number of bacteria in the tissues, 
the protection was probably achieved through the high levels 
of LDL in the LDLR—/ — mice, which are able to neutralize 
the effects of LPS released by similar bacterial loads as in the 
control mice, and consequently inhibit the induction of lethal
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Figure 4. Secreted (Fig. 4 a) and cell-associated (Fig. 4 b) cytokine 
production after in vitro stimulation of peritoneal macrophages of 
L D L R -/— and control mice. 105 peritoneal macrophages/well were 
stimulated with either LPS (1 n-g/ml) or heat-killed S. aureus (106 
CFU/well) for 24 h at 37°C. *P <  0.05 (for comparison between 
L D L R -/— and control macrophages).
concentrations of cytokines. The crucial role of cytokines in 
the response to a Gram-negative infection, independently of 
the bacterial load, has also been documented in our previous 
studies (29, 30).
The protection against the LPS component of Gram-nega- 
tive bacteria by lipoproteins is achieved either by direct neu­
tralization of LPS by forming LPS-lipoprotein complexes (8, 
9,10), or by accelerating the clearance of LPS by lipoproteins 
(11). In this respect, we considered if in our study an increased 
clearance of LPS or the direct neutralization of LPS by lipo­
proteins is playing the main role in the protection of L D L R -/— 
mice during K  pneumoniae infection. The LPS concentrations 
tended to be lower in LDLR—/— mice than in controls when 
the infection was induced by i.v. injection of K  pneumoniae. 
This may be due to increased LPS clearance, since we deter­
mined the LPS concentrations after heating the plasma before 
the assay, a procedure which liberates lipoprotein-bound LPS 
(31). However, in the i.m. K  pneumoniae  infection model, the 
LPS concentrations were similar in the L D L R - / -  and control 
mice. Since L D L R -/-  mice in this model also showed de­
creased circulating cytokines, as well as decreased mortality
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compared with control mice, we conclude that probably the 
main mechanism of protection of L D L R -/-  mice in K. pneu­
moniae infection is through direct binding and neutralization 
of LPS by lipoproteins, rather than increased clearance of en­
dotoxin. This is not surprising since the clearance of LDL, 
which is the main lipoprotein fraction increased in the 
L D L R - /-  mice, is decreased in these mice (22), due to the 
lack of the receptor.
The increased cytokine concentrations in the circulation 
during Gram-negative infections are thought to be induced by 
the LPS component of the cell wall. We have shown that 
L D L R - / -  mice were more LPS tolerant, the LPS LD50 in 
L D L R - / -  mice being increased approximately eightfold. As­
sociated with the increased protection of L D L R -/-  mice we 
observed decreased concentrations of the pro-inflammatory 
cytokines TNFa and IL-la. The L D L R -/-  mice were not 
protected against a lethal injection of these cytokines, arguing 
against a direct inactivation of circulating cytokines by lipopro­
teins, and against decreased peripheral sensitivity of L D L R -/-  
mice to TNFa or IL-1. This confirms that the protection of 
L D L R - /-  mice in lethal endotoxemia is due to an inactiva­
tion of the bacterial LPS by increased plasma lipoproteins, 
which in turn results in a blunted response of the pro- 
inflammatory cytokines.
An interesting observation was made when we evaluated 
the in-vitro cytokine production capacity of the L D L R -/-  
mice. We showed that, in contrast to the in-vivo decreased 
cytokine production after LPS challenge, the in-vitro LPS- 
stimulated cytokine production capacity of peritoneal mac­
rophages of mice with hypercholesterolemia was higher than 
in control mice. This increase was observed for all the cyto­
kines tested: TNFa, IL-la and IL-1 p. An explanation for these 
findings could be up-regulation of LPS receptors on the mac­
rophages of L D L R - / -  mice. Indeed, our LPS-binding experi­
ments showed increased specific binding of tritiated LPS to the 
macrophages of LDLR—/— mice. In normal mice, exposure to 
small LPS quantities may down-regulate its own receptors on 
the host cells, as has been shown for the CD 14 molecule on hu­
man cells (32). We hypothesize that in the L D L R -/-  mice, 
such down-regulation of LPS receptors may not occur because 
the enhanced plasma lipoproteins rapidly bind and neutralize 
the circulating endotoxin. In our experiments, stimulation with
S. aureus did not induce an enhanced cytokine production by 
the macrophages of L D L R - /-  mice, suggesting a selective 
down-regulation of LPS-receptors. Still, a direct effect of the 
high lipoprotein concentrations on the LPS receptors and LPS 
binding cannot be excluded, since others have shown that cho­
lesterol modulates CD 14 expression on human cells (33), and 
the clustering of other glycophospholipid-anchored receptors 
(34). Because LPS binds not only to CD 14, but also to CD1 lb/ 
CD18, to the scavenger receptor, and possibly other mem­
brane proteins, it remains to be elucidated which of these re­
ceptors and mechanisms contributed to the increased LPS 
binding.
An increased cytokine production capacity has also been 
observed in monocytes of patients with familial hypercholes­
terolemia (35) and in individuals with high plasma HDL con­
centrations (36). The results of these studies and our present 
findings argue for a more general phenomenon of increased 
cytokine production by monocytes/macrophages of hosts with 
high circulating lipoprotein concentrations. The clinical impor­
tance of this phenomenon remains to be further studied.
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